ClinicalTrials.gg
CompletedNCT01945021Updated Feb 21, 2021Results posted

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

A Phase 2 interventional study of Crizotinib in Non Small Cell Lung Cancer, ROS1 Proto Oncogene and Crizotinib, sponsored by Pfizer. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
8th of 23
129 · median 80
Started
2013
with 2 others
Phase 2
13 of 23
4 open now
Registered
9th of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 13 in phase 2, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an ALK mutation

03

Conditions studied

  • Non Small Cell Lung Cancer
  • ROS1 Proto Oncogene
  • Crizotinib

Keywords

  • Non small cell lung cancer
  • NSCLC
  • ROS1
  • ROS1 positive
  • ROS1 proto oncogene
  • c ros tyrosine kinases
  • ROS1 positive NSCLC
  • ROS1 lung cancer
  • ALK negative
  • Lung Carcinoma
  • Neoplasm
  • Crizotinib
  • Xalkori
  • Previously treated or untreated
  • North East Asian
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven diagnosis of NSCLC that is locally advanced or
  • treatment-naïve or have received no more than 3 systemic treatment regimen(s)
  • Positive for translocation or inversion events involving the ROS1 gene
  • Negative for translocation or inversion events involving the ALK gene
  • Patients with are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any medications
  • Any prior treatment (chemotherapy, radiation [except for palliative], or surgery) must have been completed at least 2 weeks prior to initiation of study medication
  • At least 1 measurable tumor lesion as per v1.1
  • Female or male, 18 years of age or older
  • performance status 0 to 1
  • Adequate organ function
  • Signed and dated
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the PRO measures
  • Agree to use effective during the study period and for at least 90 days after completion of the study treatment

Exclusion criteria

Exclusion Criteria:

  • Current treatment on another therapeutic clinical trial
  • Prior therapy specifically directed against ALK or ROS1 fusion genes
  • Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or
  • known interstitial fibrosis or interstitial lung disease
  • myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including within 3 months prior to start of study treatment
  • Ongoing cardiac dysrhythmias of v4.03 Grade >/=2, uncontrolled atrial fibrillation of any grade, or >470 msec
  • Pregnant or breast feeding
  • Use of drugs or foods that are known potent inhibitors or inducers
  • Use of other anti-cancer drugs including traditional Chinese medicine on the SFDA list
  • Evidence of active within last 3 years
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Crizotinib

    Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib

    Drug: Crizotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Independent Radiology Reviewed Overall Objective Response (ORR)

    Overall objective response (ORR) was defined as the number of patients with a best overall response of confirmed Complete Response or confirmed Partial Response according to RECIST v1.1 (as determined by Independent Radiology Review \[IRR\]), relative to the total population of response-evaluable participants. Per RECIST v1.1, CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.

    Time frame: Starting from the first dose study treatment until the first documented CR or PR (every 8 weeks then after 8 cycles at every 12 weeks in duration of 94.0 weeks)

Secondary outcomes

  1. IRR-Assessed Duration of Response (DR)

    DR: time from first documentation of objective tumor response (CR or PR) to first documentation of objective progressive disease (PD) or to death due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, a) PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study), sum must also demonstrate an absolute increase of \>=5 mm, appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions; b) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); c) PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.

    Time frame: From first documentation of objective tumor response to first documentation of objective PD or death due to any cause, whichever occurred first (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)

  2. IRR-Assessed Time to Tumor Response (TTR)

    TTR was defined as the time from the date of first dose to first documentation of objective tumor response (CR or PR), that was subsequently confirmed. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of first dose of crizotinib to first documentation of objective response was observed (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)

  3. IRR Assessed Disease Control Rate (DCR) at 8 Weeks

    DCR at 8 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or stable disease (SD) at 8 weeks, respectively, relative to the total population of response evaluable participants. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: At 8 weeks after the start of study treatment

  4. IRR-Assessed Progression Free Survival (PFS)

    PFS was defined as the time from the date of the first dose of crizotinib to first documentation of objective PD or to death on study due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered a sign of progression. Unequivocal progression of existing non-target lesions.

    Time frame: From the date of first dose of crizotinib until the first documentation of objective PD or death (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)

  5. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of crizotinib to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.

    Time frame: From date of the first dose of crizotinib until the date of death from any cause (up to 291.9 weeks)

  6. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs

    Treatment-emergent AEs :between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to crizotinib was assessed by the investigator. Treatment-related AE: any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE):an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death.

    Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)

  7. Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4

    Laboratory values included hemoglobin increased, anemia, platelet count decreased, leukocytosis, white blood cell decreased, lymphocyte count increased, lymphocyte count decreased and neutrophil count decreased. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.

    Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)

  8. Number of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4

    Laboratory values included blood bilirubin increased, alanine aminotransferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, hypoalbuminemia, hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypophosphatemia, Creatinine increased, hyperuricemia, hypermagnesemia, hypomagnesemia, hyperglycemia and hypoglycemia. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.

    Time frame: Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)

  9. Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores

    The EORTC QLQ-C30 consists of 30 questions which are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global QOL scale; 3 symptom scales (fatigue, pain, nausea and vomiting scales); and 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance/insomnia, constipation, and diarrhea) and the perceived financial burden of treatment. All the scales and single-item scores ranged from 0 to 100, higher score is indicative of a higher response level (high score for a functional scale represents a high / healthy level of functioning; high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems).

    Time frame: Baseline up to Cycle 60

  10. Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores

    The EORTC QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed specific symptoms (dyspnea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia). Scores on each scale and item ranged from 0 to 100, higher score is indicative of a higher response level (a high score for a symptom scale / item represents a high level of symptomatology / problems).

    Time frame: Baseline up to Cycle 60

07

Results

Posted Aug 1, 2016
Limitations and caveats
Due to small percentage of participants (less than 20%) after Cycle 60, data for EORTC QLQ-C30 score and EORTC QLQ-LC13 score could not be interpreted. 65 participants died during the whole study: 15 participants died within 28 days from last dose of study treatment and were reported as SAEs, while 50 participants died during the survival follow-up.

Participant flow

Participant flow — Overall Study
MilestoneCrizotinib 250 mg
Started127
Safety population127
Response evaluable population127
Patient reported outcome evaluable123
Completed44
Not completed83
Withdrew: Adverse event1
Withdrew: Withdrawal of consent12
Withdrew: Lost to follow-up5
Withdrew: Death65

Outcome measures

PrimaryIndependent Radiology Reviewed Overall Objective Response (ORR)

Overall objective response (ORR) was defined as the number of patients with a best overall response of confirmed Complete Response or confirmed Partial Response according to RECIST v1.1 (as determined by Independent Radiology Review \[IRR\]), relative to the total population of response-evaluable participants. Per RECIST v1.1, CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Confirmed responses were those that persisted on repeat imaging at least 4 weeks after the initial documentation of response.

Time frame:
Starting from the first dose study treatment until the first documented CR or PR (every 8 weeks then after 8 cycles at every 12 weeks in duration of 94.0 weeks)
Reported as:
Count of participants · Participants
Independent Radiology Reviewed Overall Objective Response (ORR)
ParticipantsCrizotinib 250 mg
Independent Radiology Reviewed Overall Objective Response (ORR)88
SecondaryIRR-Assessed Duration of Response (DR)

DR: time from first documentation of objective tumor response (CR or PR) to first documentation of objective progressive disease (PD) or to death due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, a) PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study), sum must also demonstrate an absolute increase of \>=5 mm, appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions; b) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); c) PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters.

Time frame:
From first documentation of objective tumor response to first documentation of objective PD or death due to any cause, whichever occurred first (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
Reported as:
Median · Months
IRR-Assessed Duration of Response (DR)
MonthsCrizotinib 250 mg
IRR-Assessed Duration of Response (DR)19.7 (14.1 to NA)
SecondaryIRR-Assessed Time to Tumor Response (TTR)

TTR was defined as the time from the date of first dose to first documentation of objective tumor response (CR or PR), that was subsequently confirmed. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of first dose of crizotinib to first documentation of objective response was observed (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
Reported as:
Median · Months
IRR-Assessed Time to Tumor Response (TTR)
MonthsCrizotinib 250 mg
IRR-Assessed Time to Tumor Response (TTR)1.9 (1.6 to 15.8)
SecondaryIRR Assessed Disease Control Rate (DCR) at 8 Weeks

DCR at 8 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or stable disease (SD) at 8 weeks, respectively, relative to the total population of response evaluable participants. RECIST v1.1 (as determined by IRR), a) CR: disappearance of all target lesions. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis); b) PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
At 8 weeks after the start of study treatment
Reported as:
Number · Percentage of participants
IRR Assessed Disease Control Rate (DCR) at 8 Weeks
Percentage of participantsCrizotinib 250 mg
IRR Assessed Disease Control Rate (DCR) at 8 Weeks88.2 (81.3 to 93.2)
SecondaryIRR-Assessed Progression Free Survival (PFS)

PFS was defined as the time from the date of the first dose of crizotinib to first documentation of objective PD or to death on study due to any cause, whichever occurred first. If no progression or death on study was observed, or given antitumor treatment other than study drug, participants were censored on date of last on-study tumor assessment. RECIST v1.1, PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered a sign of progression. Unequivocal progression of existing non-target lesions.

Time frame:
From the date of first dose of crizotinib until the first documentation of objective PD or death (every 8 weeks then after 8 cycles at every 12 weeks in duration of 151.3 weeks)
Reported as:
Median · Months
IRR-Assessed Progression Free Survival (PFS)
MonthsCrizotinib 250 mg
IRR-Assessed Progression Free Survival (PFS)15.9 (12.9 to 24.0)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of crizotinib to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.

Time frame:
From date of the first dose of crizotinib until the date of death from any cause (up to 291.9 weeks)
Reported as:
Median · Months
Overall Survival (OS)
MonthsCrizotinib 250 mg
Overall Survival (OS)44.2 (32.0 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs

Treatment-emergent AEs :between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to crizotinib was assessed by the investigator. Treatment-related AE: any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE):an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death.

Time frame:
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs
ParticipantsCrizotinib 250 mg
Incidence of All-Causality Adverse Events127
Incidence of All-Causality Serious Adverse Events46
Incidence of Treatment Related Adverse Events124
Incidence of Treatment Related Serious Adverse Events11
Incidence of All-Causality Grade 3-4 Adverse Event68
Incidence of Treatment Related Grade 3-4 Adverse Event41
SecondaryNumber of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4

Laboratory values included hemoglobin increased, anemia, platelet count decreased, leukocytosis, white blood cell decreased, lymphocyte count increased, lymphocyte count decreased and neutrophil count decreased. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.

Time frame:
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
ParticipantsCrizotinib 250 mg
Hemoglobin Increased: Baseline Grade 0 to Worst Grade 30
Hemoglobin Increased: Baseline Grade 1 to Worst Grade 30
Hemoglobin Increased: Baseline Grade 2 to Worst Grade 30
Anemia: Baseline Grade 0 to Worst Grade 32
Anemia: Baseline Grade 1 to Worst Grade 31
Anemia: Baseline Grade 2 to Worst Grade 35
Anemia: Baseline Grade 0 to Worst Grade 40
Anemia: Baseline Grade 1 to Worst Grade 40
Anemia: Baseline Grade 2 to Worst Grade 40
Platelet Count Decreased: Baseline Grade 0 to Worst Grade 30
Platelet Count Decreased: Baseline Grade 1 to Worst Grade 30
Platelet Count Decreased: Baseline Grade 2 to Worst Grade 30
Platelet Count Decreased: Baseline Grade 0 to Worst Grade 40
Platelet Count Decreased: Baseline Grade 1 to Worst Grade 40
Platelet Count Decreased: Baseline Grade 2 to Worst Grade 40
Leukocytosis: Baseline Grade 0 to Worst Grade 30
Leukocytosis: Baseline Grade 0 to Worst Grade 40
White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 33
White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 31
White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 30
White Blood Cell Decreased: Baseline Grade 0 to Worst Grade 40
White Blood Cell Decreased: Baseline Grade 1 to Worst Grade 40
White Blood Cell Decreased: Baseline Grade 2 to Worst Grade 40
Lymphocyte Count Increased: Baseline Grade 0 to Worst Grade 30
Lymphocyte Count Increased: Baseline Grade 2 to Worst Grade 30
Lymphocyte Count Decreased: Baseline Grade 0 to Worst Grade 34
Lymphocyte Count Decreased: Baseline Grade 1 to Worst Grade 30
Lymphocyte Count Decreased: Baseline Grade 2 to Worst Grade 32
Lymphocyte Count Decreased: Baseline Grade 0 to Worst Grade 40
Lymphocyte Count Decreased: Baseline Grade 1 to Worst Grade 40
Lymphocyte Count Decreased: Baseline Grade 2 to Worst Grade 40
Neutrophil Count Decreased: Baseline Grade 0 to Worst Grade 37
Neutrophil Count Decreased: Baseline Grade 1 to Worst Grade 31
Neutrophil Count Decreased: Baseline Grade 2 to Worst Grade 30
Neutrophil Count Decreased: Baseline Grade 0 to Worst Grade 44
Neutrophil Count Decreased: Baseline Grade 1 to Worst Grade 40
Neutrophil Count Decreased: Baseline Grade 2 to Worst Grade 40
SecondaryNumber of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4

Laboratory values included blood bilirubin increased, alanine aminotransferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, hypoalbuminemia, hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypophosphatemia, Creatinine increased, hyperuricemia, hypermagnesemia, hypomagnesemia, hyperglycemia and hypoglycemia. Laboratory values were defined as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher.

Time frame:
Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4
ParticipantsCrizotinib 250 mg
Blood Bilirubin Increased: Baseline Grade 0 to Worst Grade 31
Blood Bilirubin Increased: Baseline Grade 1 to Worst Grade 30
Blood Bilirubin Increased: Baseline Grade 2 to Worst Grade 30
Blood Bilirubin Increased: Baseline Grade 0 to Worst Grade 40
Blood Bilirubin Increased: Baseline Grade 1 to Worst Grade 40
Blood Bilirubin Increased: Baseline Grade 2 to Worst Grade 40
Alanine Aminotransferase Increased: Baseline Grade 0 to Worst Grade 34
Alanine Aminotransferase Increased: Baseline Grade 1 to Worst Grade 31
Alanine Aminotransferase Increased: Baseline Grade 2 to Worst Grade 30
Alanine Aminotransferase Increased: Baseline Grade 0 to Worst Grade 44
Alanine Aminotransferase Increased: Baseline Grade 1 to Worst Grade 40
Alanine Aminotransferase Increased: Baseline Grade 2 to Worst Grade 40
Aspartate Aminotransferase Increased : Baseline Grade 0 to Worst Grade 32
Aspartate Aminotransferase Increased : Baseline Grade 1 to Worst Grade 30
Aspartate Aminotransferase Increased : Baseline Grade 2 to Worst Grade 30
Aspartate Aminotransferase Increased : Baseline Grade 0 to Worst Grade 44
Aspartate Aminotransferase Increased : Baseline Grade 1 to Worst Grade 40
Aspartate Aminotransferase Increased : Baseline Grade 2 to Worst Grade 40
Alkaline Phosphatase Increased : Baseline Grade 0 to Worst Grade 30
Alkaline Phosphatase Increased : Baseline Grade 1 to Worst Grade 30
Alkaline Phosphatase Increased : Baseline Grade 2 to Worst Grade 30
Alkaline Phosphatase Increased : Baseline Grade 0 to Worst Grade 40
Alkaline Phosphatase Increased : Baseline Grade 1 to Worst Grade 40
Alkaline Phosphatase Increased : Baseline Grade 2 to Worst Grade 40
Hypoalbuminemia: Baseline Grade 0 to Worst Grade 31
Hypoalbuminemia: Baseline Grade 1 to Worst Grade 31
Hypoalbuminemia: Baseline Grade 2 to Worst Grade 31
Hypoalbuminemia: Baseline Grade 0 to Worst Grade 40
Hypoalbuminemia: Baseline Grade 1 to Worst Grade 40
Hypoalbuminemia: Baseline Grade 2 to Worst Grade 40
Hypernatremia: Baseline Grade 0 to Worst Grade 30
Hypernatremia: Baseline Grade 1 to Worst Grade 30
Hypernatremia: Baseline Grade 2 to Worst Grade 30
Hypernatremia: Baseline Grade 0 to Worst Grade 40
Hypernatremia: Baseline Grade 1 to Worst Grade 40
Hypernatremia: Baseline Grade 2 to Worst Grade 40
Hyponatremia: Baseline Grade 0 to Worst Grade 38
Hyponatremia: Baseline Grade 1 to Worst Grade 34
Hyponatremia: Baseline Grade 0 to Worst Grade 40
Hyponatremia: Baseline Grade 1 to Worst Grade 40
Hyperkalemia: Baseline Grade 0 to Worst Grade 30
Hyperkalemia: Baseline Grade 1 to Worst Grade 31
Hyperkalemia: Baseline Grade 2 to Worst Grade 30
Hyperkalemia: Baseline Grade 0 to Worst Grade 40
Hyperkalemia: Baseline Grade 1 to Worst Grade 40
Hyperkalemia: Baseline Grade 2 to Worst Grade 40
Hypokalemia: Baseline Grade 0 to Worst Grade 35
Hypokalemia: Baseline Grade 1 to Worst Grade 30
Hypokalemia: Baseline Grade 2 to Worst Grade 30
Hypokalemia: Baseline Grade 0 to Worst Grade 41
Hypokalemia: Baseline Grade 1 to Worst Grade 40
Hypokalemia: Baseline Grade 2 to Worst Grade 40
Hypercalcemia: Baseline Grade 0 to Worst Grade 30
Hypercalcemia: Baseline Grade 1 to Worst Grade 30
Hypercalcemia: Baseline Grade 2 to Worst Grade 30
Hypercalcemia: Baseline Grade 0 to Worst Grade 40
Hypercalcemia: Baseline Grade 1 to Worst Grade 40
Hypercalcemia: Baseline Grade 2 to Worst Grade 40
Hypocalcemia: Baseline Grade 0 to Worst Grade 30
Hypocalcemia: Baseline Grade 1 to Worst Grade 30
Hypocalcemia: Baseline Grade 2 to Worst Grade 30
Hypocalcemia: Baseline Grade 0 to Worst Grade 40
Hypocalcemia: Baseline Grade 1 to Worst Grade 40
Hypocalcemia: Baseline Grade 2 to Worst Grade 40
Hypophosphatemia: Baseline Grade 0 to Worst Grade 311
Hypophosphatemia: Baseline Grade 1 to Worst Grade 30
Hypophosphatemia: Baseline Grade 2 to Worst Grade 31
Hypophosphatemia: Baseline Grade 0 to Worst Grade 41
Hypophosphatemia: Baseline Grade 1 to Worst Grade 40
Hypophosphatemia: Baseline Grade 2 to Worst Grade 40
Creatinine Increased: Baseline Grade 0 to Worst Grade 31
Creatinine Increased: Baseline Grade 1 to Worst Grade 30
Creatinine Increased: Baseline Grade 2 to Worst Grade 30
Creatinine Increased: Baseline Grade 0 to Worst Grade 40
Creatinine Increased: Baseline Grade 1 to Worst Grade 40
Creatinine Increased: Baseline Grade 2 to Worst Grade 40
Hyperuricemia: Baseline Grade 0 to Worst Grade 333
Hyperuricemia: Baseline Grade 1 to Worst Grade 30
Hyperuricemia: Baseline Grade 0 to Worst Grade 40
Hyperuricemia: Baseline Grade 1 to Worst Grade 40
Hypermagnesemia: Baseline Grade 0 to Worst Grade 32
Hypermagnesemia: Baseline Grade 1 to Worst Grade 30
Hypermagnesemia: Baseline Grade 0 to Worst Grade 40
Hypermagnesemia: Baseline Grade 1 to Worst Grade 40
Hypomagnesemia: Baseline Grade 0 to Worst Grade 30
Hypomagnesemia: Baseline Grade 1 to Worst Grade 30
Hypomagnesemia: Baseline Grade 2 to Worst Grade 30
Hypomagnesemia: Baseline Grade 0 to Worst Grade 40
Hypomagnesemia: Baseline Grade 1 to Worst Grade 40
Hypomagnesemia: Baseline Grade 2 to Worst Grade 40
Hyperglycemia: Baseline Grade 0 to Worst Grade 31
Hyperglycemia: Baseline Grade 1 to Worst Grade 31
Hyperglycemia: Baseline Grade 2 to Worst Grade 30
Hyperglycemia: Baseline Grade 0 to Worst Grade 40
Hyperglycemia: Baseline Grade 1 to Worst Grade 40
Hyperglycemia: Baseline Grade 2 to Worst Grade 40
Hypoglycemia: Baseline Grade 0 to Worst Grade 30
Hypoglycemia: Baseline Grade 1 to Worst Grade 30
Hypoglycemia: Baseline Grade 2 to Worst Grade 30
Hypoglycemia: Baseline Grade 0 to Worst Grade 40
Hypoglycemia: Baseline Grade 1 to Worst Grade 40
Hypoglycemia: Baseline Grade 2 to Worst Grade 40
SecondaryChange From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores

The EORTC QLQ-C30 consists of 30 questions which are incorporated into 5 functional domains (physical, role, cognitive, emotional, and social); a global health status/global QOL scale; 3 symptom scales (fatigue, pain, nausea and vomiting scales); and 6 single items that assess the additional symptoms (dyspnea, appetite loss, sleep disturbance/insomnia, constipation, and diarrhea) and the perceived financial burden of treatment. All the scales and single-item scores ranged from 0 to 100, higher score is indicative of a higher response level (high score for a functional scale represents a high / healthy level of functioning; high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems).

Time frame:
Baseline up to Cycle 60
Reported as:
Mean · Units on a scale
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores
Units on a scaleCrizotinib 250 mg
Global Health Status11.85 ± 20.844
Physical Functioning3.08 ± 11.964
Role Functioning-0.65 ± 17.945
Emotional Functioning10.77 ± 18.146
Cognitive Functioning3.20 ± 14.159
Social Functioning5.13 ± 20.961
Fatigue-12.30 ± 20.156
Nausea and Vomiting0.64 ± 14.517
Pain-12.18 ± 16.027
Dyspnea-6.41 ± 21.124
Insomnia-11.53 ± 16.161
Appetite loss-14.10 ± 23.428
Constipation10.26 ± 27.920
Diarrhoea1.28 ± 19.937
Financial difficulties-21.80 ± 28.199
SecondaryChange From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores

The EORTC QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed specific symptoms (dyspnea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia). Scores on each scale and item ranged from 0 to 100, higher score is indicative of a higher response level (a high score for a symptom scale / item represents a high level of symptomatology / problems).

Time frame:
Baseline up to Cycle 60
Reported as:
Mean · Units on a scale
Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores
Units on a scaleCrizotinib 250 mg
Dyspnea-4.74 ± 14.791
Coughing-12.82 ± 29.936
Hemoptysis-5.12 ± 12.253
Sore mouth-1.28 ± 14.844
Dysphagia0.00 ± 16.314
Peripheral neuropathy3.85 ± 19.611
Alopecia-2.57 ± 20.910
Pain in chest-12.82 ± 21.236
Pain in arm or shoulder-15.37 ± 23.536
Pain in other parts-7.68 ± 21.718

Adverse events

Collected over Baseline up to 28 days after the last dose of study treatment (maximum up to 295.9 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib 250 mg65/127 (51.2%)46/127 (36.2%)127/127 (100%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventCrizotinib 250 mg
PneumoniaInfections and infestations10/127
Disease ProgressionGeneral disorders7/127
Respiratory failureRespiratory, thoracic and mediastinal disorders5/127
Pleural effusionRespiratory, thoracic and mediastinal disorders3/127
Hepatic function abnormalHepatobiliary disorders2/127
Alanine aminotransferase increasedInvestigations2/127
Renal cystRenal and urinary disorders2/127
Deep vein thrombosisVascular disorders2/127
Acute myocardial infarctionCardiac disorders1/127
Abdominal painGastrointestinal disorders1/127
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCrizotinib 250 mg
Alanine aminotransferase increasedInvestigations72/127
Aspartate aminotransferase increasedInvestigations67/127
DiarrhoeaGastrointestinal disorders62/127
NauseaGastrointestinal disorders58/127
VomitingGastrointestinal disorders50/127
ConstipationGastrointestinal disorders49/127
Oedema peripheralGeneral disorders39/127
Neutrophil count decreasedInvestigations37/127
CoughRespiratory, thoracic and mediastinal disorders35/127
White blood cell count decreasedInvestigations30/127

Baseline characteristics

The Safety Population contains all enrolled participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Crizotinib 250 mg
Mean52.48 ± 12.136
Sex: Female, Male
Sex: Female, Male(Participants)Crizotinib 250 mg
Female73
Male54
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Crizotinib 250 mg
Asian127
Region of Enrollment
Region of Enrollment(Participants)Crizotinib 250 mg
Asia — China74
Asia — Japan26
Asia — Korea12
Asia — Taiwan15
08

Study locations

44 sites
  • The First Affiliated Hospital of Anhui Medical University, Department of Medical Oncology
    Hefei, Anhui 230022, China
  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Chaoyang District, Beijing 100021, China
  • The Military General Hospital of Beijing PLA / Medical Oncology Dept.
    Dongcheng District, Beijing 100700, China
  • 307 Hospital of PLA/Department of Lung Cancer
    Fengtai District, Beijing 100071, China
  • Beijing Cancer Hospital, Department of Thoracic Oncology
    Haidian District, Beijing 100142, China
  • Chinese PLA General Hospital
    Haidian District, Beijing 100853, China
  • Beijing Chest Hospital
    Tongzhou District, Beijing, China
  • Respiration department,the First Affiliated Hospital of Third Military Medical University, PLA
    Shapingba District, Chongqing 400038, China
  • Fujian Province Oncology Hospital
    Fuzhou, Fujian 350014, China
  • SUN Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • The First Affiliated Hospital of Guangzhou Medical College
    Guangzhou, Guangdong 510120, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Hunan Provincial Tumor Hospital/Division of Oncology
    Changsha, Hunan 410013, China
  • Department of Oncology, Jilin Provincial Cancer Hospital
    Changchun, Jilin, China
  • The affiliated hospital of medical college Qingdao University / Medical oncology department
    Qingdao, Shandong 266101, China
  • Department of Pulmonary Medicine, Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
  • Shanghai Chest Hospital/Lung cancer clinical center
    Shanghai, Shanghai 200030, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
  • Zhongshan Hospital Fudan University / Respiratory Department
    Xuhui District, Shanghai 200032, China
  • Oncology Department, West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
    Chengdu, Sichuan 610041, China
  • Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital
    Hexi District, Tianjin 300060, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
  • Aichi Cancer Center Hospital
    Aichi, Japan
  • National Cancer Center Hospital East
    Chiba, Japan
  • NHO Shikoku Cancer Center
    Ehime, Japan
  • NHO Kyushu Cancer Center
    Fukuoka, Japan
  • Hyogo Cancer Center
    Hyogo, Japan
  • Tohoku University Hospital
    Miyagi, Japan
  • Kinki University Hospital
    Osaka, Japan
  • Osaka City General Hospital
    Osaka, Japan
  • Cancer Institute Hospital of JFCR
    Tokyo, Japan
  • National Cancer Center Hospital
    Tokyo, Japan
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Yonsei University, Severance Hospital
    Seoul, Korea, Republic of
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
09

References and documents

Publications

  • Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 May 10;36(14):1405-1411. doi: 10.1200/JCO.2017.75.5587. Epub 2018 Mar 29. PubMed 29596029 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jul 2015, 22 months.

Results were first posted in Aug 2016, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2013
First posted
Sep 18, 2013
StartActual
Sep 30, 2013
Primary completionActual
Jul 31, 2015
CompletionActual
Jan 22, 2020
Results first posted
Aug 1, 2016
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01945021
Lead sponsor
Pfizer
Collaborators
OxOnc Development LP
Responsible party
Sponsor
First posted
Sep 18, 2013
Start date
Sep 30, 2013
Primary completion
Jul 31, 2015
Completion
Jan 22, 2020
Results posted
Aug 1, 2016
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion